DoW Arthritis Translational Research Award

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged. Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions. Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.

See opportunity page for eligibility details.